SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-068283
Filing Date
2022-06-06
Accepted
2022-06-06 06:30:33
Documents
14
Period of Report
2022-06-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2217756d1_8k.htm   iXBRL 8-K 27545
2 EXHIBIT 99.1 tm2217756d1_ex99-1.htm EX-99.1 14214
6 GRAPHIC tm2217756d1_ex99-1img01.jpg GRAPHIC 2933
  Complete submission text file 0001104659-22-068283.txt   223341

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA icpt-20220606.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20220606_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20220606_pre.xml EX-101.PRE 22609
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2217756d1_8k_htm.xml XML 3498
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 22996663
SIC: 2834 Pharmaceutical Preparations